European Society for Medical Oncology Congress

The latest news from ESMO, including researcher interviews and physician perspective.


Meeting News

Cediranib plus olaparib effective, safe for recurrent, platinum-resistant ovarian cancer

September 28, 2019
BARCELONA, Spain — The combination of cediranib and olaparib appeared to be effective and safe for women with heavily pretreated…
Meeting NewsPerspective

Apalutamide improves OS in nonmetastatic, castration-resistant prostate cancer

September 27, 2019
BARCELONA, Spain — Apalutamide with ongoing androgen deprivation therapy significantly improved OS compared with placebo among men with…
Meeting NewsPerspective

Addition of docetaxel to androgren deprivation confers durable OS benefit for metastatic prostate cancer

September 27, 2019
BARCELONA, Spain — The addition of upfront docetaxel chemotherapy to androgen deprivation therapy conferred durable, clinically significant…
Meeting NewsPerspective

Atezolizumab extends OS for PD-L1-selected patients with non-small cell lung cancer

September 27, 2019
BARCELONA, Spain — Atezolizumab significantly prolonged OS compared with platinum-based chemotherapy for patients with newly diagnosed…
Meeting NewsPerspective

HCC trial misses OS endpoint, but researchers report ‘clinically meaningful’ benefit with nivolumab

September 27, 2019
BARCELONA, Spain — Nivolumab did not significantly extend OS compared with sorafenib as first-line therapy for patients with advanced…

ESMO honors several oncology leaders

October 31, 2018
European Society for Medical Oncology honored several oncology leaders during its annual congress. Jean-Charles Soria, MD, PhD, received the…
Meeting NewsPerspective

Neoadjuvant ipilimumab-nivolumab combination induces major pathological response in mismatch repair-deficient colon cancer

October 29, 2018
MUNICH — Neoadjuvant treatment with nivolumab and ipilimumab induced major pathologic response in 100% of patients with early-stage, mismatch…
Meeting News

Nivolumab plus low-dose ipilimumab demonstrates ‘robust’ benefit for certain patients with metastatic colorectal cancer

October 29, 2018
MUNICH — The combination of nivolumab and low-dose ipilimumab may become a new first-line treatment option for patients with microsatellite…
Meeting NewsPerspective

Chemoradiation should remain standard for HPV-positive oropharyngeal cancer

October 22, 2018
MUNICH — Patients with HPV-positive, low-risk oropharyngeal cancer should undergo chemoradiotherapy instead of cetuximab plus radiotherapy…
Meeting NewsPerspective

First-line pembrolizumab a new standard for recurrent, metastatic head and neck squamous cell carcinoma

October 22, 2018
MUNICH — Pembrolizumab prolonged survival compared with standard first-line systemic therapy for patients with recurrent or metastatic head and…